Supplements

A supplement to Skin & Allergy News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

•Topic Highlights/Faculty
•Target Audience

To view the supplement, click the image above.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

•Topic Highlights/Faculty
•Target Audience

To view the supplement, click the image above.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

•Topic Highlights/Faculty
•Target Audience

To view the supplement, click the image above.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Warner Chilcott.
This supplement to Skin & Allergy News is based on an expert roundtable as well as a presentation made at Skin Disease Education Foundation's 7th Annual Las Vegas Dermatology Seminar, a continuing medical education program, held November 10-12, 2006 in Las Vegas, Nevada.

•Topics
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

• Introduction
• Current Topical Therapies for Psoriasis
• Efficacy of a Novel 2-Compound Ointment
• Safety Profile of a Novel 2-Compound Ointment
• Role of a 2-Compound Ointment in the Treatment Armamentarium for Psoriasis Vulgaris

Faculty/Faculty Disclosure Statement

Craig Leonardi, MD—Chair
Associate Clinical Professor of Dermatology
Saint Louis University
St. Louis, Missouri
Dr. Leonardi is a consultant for Abbott Laboratories, Amgen, Inc., Centocor, Inc., and Genentech, Inc. He has been an investigator for Abbott, Allergan, Inc., Altana, Inc., Amgen, Astellas Pharma US, Bristol-Myers Squibb, Centocor, CombinatoRx, Galderma Laboratories, L.P., Genentech, Novartis Pharmaceuticals, RTL, Schering-Plough Corporation, 3M Pharmaceuticals, and Vitae Pharmaceuticals. He is on the speakers' bureau for Abbott, Amgen, Centocor, Genentech, and Warner Chilcott (US), Inc.

Jerry Bagel, MD
Director of the Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Clinical Assistant Professor of Dermatology
College of Physicians and Surgeons at Columbia University
New York, New York
Dr. Bagel speaks for Abbott, Amgen, Astellas, Genentech, Novartis, and Warner Chilcott. He is an investigator for Amgen, Astellas, Centocor, and Galderma.

Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York, New York
Dr. Lebwohl is a consultant for or has pending consulting agreements for Abbott, Amgen, Astellas, Bristol-Myers Squibb, Centocor, Connetics Pharmaceuticals, Galderma, Genentech, Novartis, Pfizer, Inc., 3M, and Warner Chilcott. In the last 12 months, he has served as a speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, Novartis, PharmaDerm, 3M, and Warner Chilcott.

Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan
Dr. Gold is a principal investigator, consultant, and member of the speakers' bureau for Connetics, Galderma, and Warner Chilcott. She is a member of the speakers' bureau and a consultant for Genentech, and she is also a principal investigator for Astellas.

The participants discuss using the 2-compound ointment beyond the 4 weeks indicated by the product labeling.

A supplement to Skin & Allergy News and supported by Warner Chilcott.
This supplement to Skin & Allergy News is based on an expert roundtable as well as a presentation made at Skin Disease Education Foundation's 7th Annual Las Vegas Dermatology Seminar, a continuing medical education program, held November 10-12, 2006 in Las Vegas, Nevada.

•Topics
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

• Introduction
• Current Topical Therapies for Psoriasis
• Efficacy of a Novel 2-Compound Ointment
• Safety Profile of a Novel 2-Compound Ointment
• Role of a 2-Compound Ointment in the Treatment Armamentarium for Psoriasis Vulgaris

Faculty/Faculty Disclosure Statement

Craig Leonardi, MD—Chair
Associate Clinical Professor of Dermatology
Saint Louis University
St. Louis, Missouri
Dr. Leonardi is a consultant for Abbott Laboratories, Amgen, Inc., Centocor, Inc., and Genentech, Inc. He has been an investigator for Abbott, Allergan, Inc., Altana, Inc., Amgen, Astellas Pharma US, Bristol-Myers Squibb, Centocor, CombinatoRx, Galderma Laboratories, L.P., Genentech, Novartis Pharmaceuticals, RTL, Schering-Plough Corporation, 3M Pharmaceuticals, and Vitae Pharmaceuticals. He is on the speakers' bureau for Abbott, Amgen, Centocor, Genentech, and Warner Chilcott (US), Inc.

Jerry Bagel, MD
Director of the Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Clinical Assistant Professor of Dermatology
College of Physicians and Surgeons at Columbia University
New York, New York
Dr. Bagel speaks for Abbott, Amgen, Astellas, Genentech, Novartis, and Warner Chilcott. He is an investigator for Amgen, Astellas, Centocor, and Galderma.

Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York, New York
Dr. Lebwohl is a consultant for or has pending consulting agreements for Abbott, Amgen, Astellas, Bristol-Myers Squibb, Centocor, Connetics Pharmaceuticals, Galderma, Genentech, Novartis, Pfizer, Inc., 3M, and Warner Chilcott. In the last 12 months, he has served as a speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, Novartis, PharmaDerm, 3M, and Warner Chilcott.

Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan
Dr. Gold is a principal investigator, consultant, and member of the speakers' bureau for Connetics, Galderma, and Warner Chilcott. She is a member of the speakers' bureau and a consultant for Genentech, and she is also a principal investigator for Astellas.

The participants discuss using the 2-compound ointment beyond the 4 weeks indicated by the product labeling.

A supplement to Skin & Allergy News and supported by Warner Chilcott.
This supplement to Skin & Allergy News is based on an expert roundtable as well as a presentation made at Skin Disease Education Foundation's 7th Annual Las Vegas Dermatology Seminar, a continuing medical education program, held November 10-12, 2006 in Las Vegas, Nevada.

•Topics
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

• Introduction
• Current Topical Therapies for Psoriasis
• Efficacy of a Novel 2-Compound Ointment
• Safety Profile of a Novel 2-Compound Ointment
• Role of a 2-Compound Ointment in the Treatment Armamentarium for Psoriasis Vulgaris

Faculty/Faculty Disclosure Statement

Craig Leonardi, MD—Chair
Associate Clinical Professor of Dermatology
Saint Louis University
St. Louis, Missouri
Dr. Leonardi is a consultant for Abbott Laboratories, Amgen, Inc., Centocor, Inc., and Genentech, Inc. He has been an investigator for Abbott, Allergan, Inc., Altana, Inc., Amgen, Astellas Pharma US, Bristol-Myers Squibb, Centocor, CombinatoRx, Galderma Laboratories, L.P., Genentech, Novartis Pharmaceuticals, RTL, Schering-Plough Corporation, 3M Pharmaceuticals, and Vitae Pharmaceuticals. He is on the speakers' bureau for Abbott, Amgen, Centocor, Genentech, and Warner Chilcott (US), Inc.

Jerry Bagel, MD
Director of the Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Clinical Assistant Professor of Dermatology
College of Physicians and Surgeons at Columbia University
New York, New York
Dr. Bagel speaks for Abbott, Amgen, Astellas, Genentech, Novartis, and Warner Chilcott. He is an investigator for Amgen, Astellas, Centocor, and Galderma.

Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York, New York
Dr. Lebwohl is a consultant for or has pending consulting agreements for Abbott, Amgen, Astellas, Bristol-Myers Squibb, Centocor, Connetics Pharmaceuticals, Galderma, Genentech, Novartis, Pfizer, Inc., 3M, and Warner Chilcott. In the last 12 months, he has served as a speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, Novartis, PharmaDerm, 3M, and Warner Chilcott.

Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan
Dr. Gold is a principal investigator, consultant, and member of the speakers' bureau for Connetics, Galderma, and Warner Chilcott. She is a member of the speakers' bureau and a consultant for Genentech, and she is also a principal investigator for Astellas.

The participants discuss using the 2-compound ointment beyond the 4 weeks indicated by the product labeling.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 31st Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Advances in Cellulite Treatment and Dermatologic Use of Mesotherapy
• Fractionated Delivery of Laser Energy Continues Evolution, Clinical Expansion
• Photodynamic Therapy's Efficacy Draws Strong Testimonials
• Proper Technique Delivers Optimal Filler Effects
• Tailor Cosmesis to Patients of Color
• Patience, Patients: Some Laser Results Are Subtle
• Glycerol
• Patient Expectations Play a Role in Botox Effects
• Small Anesthetic Changes Can Have Big Impact on Blepharoplasty Results

Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, N.Y.
Dr. Goldberg has received clinical grants from Alma Lasers Inc. He is a consultant to Photo Therapeutics Inc., and Ultrashape Inc. He discusses the off-label use of cellulite treatments.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Dr. Zachary has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 31st Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Advances in Cellulite Treatment and Dermatologic Use of Mesotherapy
• Fractionated Delivery of Laser Energy Continues Evolution, Clinical Expansion
• Photodynamic Therapy's Efficacy Draws Strong Testimonials
• Proper Technique Delivers Optimal Filler Effects
• Tailor Cosmesis to Patients of Color
• Patience, Patients: Some Laser Results Are Subtle
• Glycerol
• Patient Expectations Play a Role in Botox Effects
• Small Anesthetic Changes Can Have Big Impact on Blepharoplasty Results

Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, N.Y.
Dr. Goldberg has received clinical grants from Alma Lasers Inc. He is a consultant to Photo Therapeutics Inc., and Ultrashape Inc. He discusses the off-label use of cellulite treatments.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Dr. Zachary has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 31st Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Advances in Cellulite Treatment and Dermatologic Use of Mesotherapy
• Fractionated Delivery of Laser Energy Continues Evolution, Clinical Expansion
• Photodynamic Therapy's Efficacy Draws Strong Testimonials
• Proper Technique Delivers Optimal Filler Effects
• Tailor Cosmesis to Patients of Color
• Patience, Patients: Some Laser Results Are Subtle
• Glycerol
• Patient Expectations Play a Role in Botox Effects
• Small Anesthetic Changes Can Have Big Impact on Blepharoplasty Results

Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, N.Y.
Dr. Goldberg has received clinical grants from Alma Lasers Inc. He is a consultant to Photo Therapeutics Inc., and Ultrashape Inc. He discusses the off-label use of cellulite treatments.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Dr. Zachary has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement is based on a symposium held on July 25, 2003, in Chicago, and supported by an educational grant from Johnson & Johnson Consumer Products Company.

•TOPICS/FACULTY/FACULTY DISCLOSURES
 

To view the supplement, click the image above.

Stratum Corneum Integrity is the Key to "Sensitive Skin"
James J. Leyden, MD
Professor Emeritus of Dermatology
University of Pennsylvania
Philadelphia, PA
Dr. Leyden has received grant/research support from Johnson & Johnson and Ortho. He is also a consultant to and on the Speaker's Bureau of Ortho.

Cosmeceuticals: A New Category of Skin Care Agents
Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
University of Miami
Miami, FL
Dr. Baumann has received grant/research support from Allergan, Inc., Elan, Galderma, Inamed, and Ligand Pharmaceuticals Incorporated.

Ancient Skin Remedies Come of Age for Today's Health-Conscious Consumers
Jeanine B. Downie, MD
Director
Image Dermatology
Montclair, NJ
Dr. Downie is a consultant/scientific advisor to Allergan, Bobbie Brown, Galderma, Johnson & Johnson, and Skin Salon Gold.

Several Active Naturals Aid in the Prevention of Photoaging
Zoe D. Draelos, MD
Clinical Associate Professor
Wake Forest School of Medicine
Winston-Salem, N.C.
Dr. Draelos has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement is based on a symposium held on July 25, 2003, in Chicago, and supported by an educational grant from Johnson & Johnson Consumer Products Company.

•TOPICS/FACULTY/FACULTY DISCLOSURES
 

To view the supplement, click the image above.

Stratum Corneum Integrity is the Key to "Sensitive Skin"
James J. Leyden, MD
Professor Emeritus of Dermatology
University of Pennsylvania
Philadelphia, PA
Dr. Leyden has received grant/research support from Johnson & Johnson and Ortho. He is also a consultant to and on the Speaker's Bureau of Ortho.

Cosmeceuticals: A New Category of Skin Care Agents
Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
University of Miami
Miami, FL
Dr. Baumann has received grant/research support from Allergan, Inc., Elan, Galderma, Inamed, and Ligand Pharmaceuticals Incorporated.

Ancient Skin Remedies Come of Age for Today's Health-Conscious Consumers
Jeanine B. Downie, MD
Director
Image Dermatology
Montclair, NJ
Dr. Downie is a consultant/scientific advisor to Allergan, Bobbie Brown, Galderma, Johnson & Johnson, and Skin Salon Gold.

Several Active Naturals Aid in the Prevention of Photoaging
Zoe D. Draelos, MD
Clinical Associate Professor
Wake Forest School of Medicine
Winston-Salem, N.C.
Dr. Draelos has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement is based on a symposium held on July 25, 2003, in Chicago, and supported by an educational grant from Johnson & Johnson Consumer Products Company.

•TOPICS/FACULTY/FACULTY DISCLOSURES
 

To view the supplement, click the image above.

Stratum Corneum Integrity is the Key to "Sensitive Skin"
James J. Leyden, MD
Professor Emeritus of Dermatology
University of Pennsylvania
Philadelphia, PA
Dr. Leyden has received grant/research support from Johnson & Johnson and Ortho. He is also a consultant to and on the Speaker's Bureau of Ortho.

Cosmeceuticals: A New Category of Skin Care Agents
Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
University of Miami
Miami, FL
Dr. Baumann has received grant/research support from Allergan, Inc., Elan, Galderma, Inamed, and Ligand Pharmaceuticals Incorporated.

Ancient Skin Remedies Come of Age for Today's Health-Conscious Consumers
Jeanine B. Downie, MD
Director
Image Dermatology
Montclair, NJ
Dr. Downie is a consultant/scientific advisor to Allergan, Bobbie Brown, Galderma, Johnson & Johnson, and Skin Salon Gold.

Several Active Naturals Aid in the Prevention of Photoaging
Zoe D. Draelos, MD
Clinical Associate Professor
Wake Forest School of Medicine
Winston-Salem, N.C.
Dr. Draelos has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This educational supplement was supported by Johnson & Johnson Consumer Products Company.

•Guest Editor/Disclosure Statement
•Topic Highlights
 

To view the supplement, click the image above.

Leslie Baumann, MD
Professor of Dermatology
Chief, Division of Cosmetic Dermatology
University of Miami
Miami, Fla.
Dr. Baumann has received funding for clinical research from Avon Products, Inc., Galderma Laboratories, L.P., Johnson & Johnson Consumer Companies, Inc., and Stiefel Laboratories, Inc. She is also a speaker for Aveeno, L'Oreal, and Philosophy. Dr. Baumann is on the editorial advisory board of Skin & Allergy News.

Topic Highlights

• Introduction: Applying Nature to Dermatology Practice
• Rosemary
• Polypodium Leucotomos
• Propolis
• Oatmeal
• Olive Oil
• Dexpanthenol
• Grape Seed Extract
• Lavender
• Chamomile
• Soy and Its Isoflavones
• Vitamin A, Retinol, and Retinoids
• Vitamin E
• Green Tea
• Tea Tree Oil

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This educational supplement was supported by Johnson & Johnson Consumer Products Company.

•Guest Editor/Disclosure Statement
•Topic Highlights
 

To view the supplement, click the image above.

Leslie Baumann, MD
Professor of Dermatology
Chief, Division of Cosmetic Dermatology
University of Miami
Miami, Fla.
Dr. Baumann has received funding for clinical research from Avon Products, Inc., Galderma Laboratories, L.P., Johnson & Johnson Consumer Companies, Inc., and Stiefel Laboratories, Inc. She is also a speaker for Aveeno, L'Oreal, and Philosophy. Dr. Baumann is on the editorial advisory board of Skin & Allergy News.

Topic Highlights

• Introduction: Applying Nature to Dermatology Practice
• Rosemary
• Polypodium Leucotomos
• Propolis
• Oatmeal
• Olive Oil
• Dexpanthenol
• Grape Seed Extract
• Lavender
• Chamomile
• Soy and Its Isoflavones
• Vitamin A, Retinol, and Retinoids
• Vitamin E
• Green Tea
• Tea Tree Oil

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This educational supplement was supported by Johnson & Johnson Consumer Products Company.

•Guest Editor/Disclosure Statement
•Topic Highlights
 

To view the supplement, click the image above.

Leslie Baumann, MD
Professor of Dermatology
Chief, Division of Cosmetic Dermatology
University of Miami
Miami, Fla.
Dr. Baumann has received funding for clinical research from Avon Products, Inc., Galderma Laboratories, L.P., Johnson & Johnson Consumer Companies, Inc., and Stiefel Laboratories, Inc. She is also a speaker for Aveeno, L'Oreal, and Philosophy. Dr. Baumann is on the editorial advisory board of Skin & Allergy News.

Topic Highlights

• Introduction: Applying Nature to Dermatology Practice
• Rosemary
• Polypodium Leucotomos
• Propolis
• Oatmeal
• Olive Oil
• Dexpanthenol
• Grape Seed Extract
• Lavender
• Chamomile
• Soy and Its Isoflavones
• Vitamin A, Retinol, and Retinoids
• Vitamin E
• Green Tea
• Tea Tree Oil

Copyright © 2006 Elsevier Inc.

Proceedings of a Clinical Roundtable
A supplement to Skin & Allergy News
Supported by Chester Valley Pharmaceuticals.
The articles in this supplement are based on a faculty clinical roundtable discussion. It was produced in affiliation with Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, a medical education program held February 11-18, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
 

To view the supplement, click the image above.

• Introduction: The Clinical Landscape of Atopic Dermatitis
• Recent Developments in the Management of Atopic Dermatitis
• Quality-of-Life Issues
• Infection in Atopic Dermatitis
• Conventional Treatment Options: Corticosteroids, Calcineurin Inhibitors
• Safety Issues
• New Nonsteroidal Option

Faculty/Faculty Disclosure Statement

Lawrence F. Eichenfield, MD, Chair
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Chief, Pediatric and Adolescent Dermatology
Medical Director of Research
Children's Hospital and Health Center
San Diego
Dr. Eichenfield has received funding for a clinical study from Sinclair Pharma PLC.

Sarah L. Chamlin, MD
Assistant Professor of Pediatrics and Dermatology
Children's Memorial Hospital, Chicago
Northwestern University, Feinberg School of Medicine
Chicago
Dr. Chamlin is a consultant to Astellas Pharma Inc.

Sheila Fallon Friedlander, MD
Director, Fellowship Training Program
Pediatric and Adolescent Dermatology
Children's Hospital and Health Center, San Diego
Clinical Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Dr. Friedlander is a consultant to Astellas, Connetics Corporation, GlaxoSmithKline, and Novartis AG.

Wm. Philip Werschler, MD, FAAD, FAACS
Assistant Clinical Professor in Medicine/Dermatology
University of Washington
Seattle
Dr. Werschler has nothing to disclose.

Copyright © 2006 Elsevier Inc.

Proceedings of a Clinical Roundtable
A supplement to Skin & Allergy News
Supported by Chester Valley Pharmaceuticals.
The articles in this supplement are based on a faculty clinical roundtable discussion. It was produced in affiliation with Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, a medical education program held February 11-18, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
 

To view the supplement, click the image above.

• Introduction: The Clinical Landscape of Atopic Dermatitis
• Recent Developments in the Management of Atopic Dermatitis
• Quality-of-Life Issues
• Infection in Atopic Dermatitis
• Conventional Treatment Options: Corticosteroids, Calcineurin Inhibitors
• Safety Issues
• New Nonsteroidal Option

Faculty/Faculty Disclosure Statement

Lawrence F. Eichenfield, MD, Chair
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Chief, Pediatric and Adolescent Dermatology
Medical Director of Research
Children's Hospital and Health Center
San Diego
Dr. Eichenfield has received funding for a clinical study from Sinclair Pharma PLC.

Sarah L. Chamlin, MD
Assistant Professor of Pediatrics and Dermatology
Children's Memorial Hospital, Chicago
Northwestern University, Feinberg School of Medicine
Chicago
Dr. Chamlin is a consultant to Astellas Pharma Inc.

Sheila Fallon Friedlander, MD
Director, Fellowship Training Program
Pediatric and Adolescent Dermatology
Children's Hospital and Health Center, San Diego
Clinical Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Dr. Friedlander is a consultant to Astellas, Connetics Corporation, GlaxoSmithKline, and Novartis AG.

Wm. Philip Werschler, MD, FAAD, FAACS
Assistant Clinical Professor in Medicine/Dermatology
University of Washington
Seattle
Dr. Werschler has nothing to disclose.

Copyright © 2006 Elsevier Inc.

Proceedings of a Clinical Roundtable
A supplement to Skin & Allergy News
Supported by Chester Valley Pharmaceuticals.
The articles in this supplement are based on a faculty clinical roundtable discussion. It was produced in affiliation with Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, a medical education program held February 11-18, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
 

To view the supplement, click the image above.

• Introduction: The Clinical Landscape of Atopic Dermatitis
• Recent Developments in the Management of Atopic Dermatitis
• Quality-of-Life Issues
• Infection in Atopic Dermatitis
• Conventional Treatment Options: Corticosteroids, Calcineurin Inhibitors
• Safety Issues
• New Nonsteroidal Option

Faculty/Faculty Disclosure Statement

Lawrence F. Eichenfield, MD, Chair
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Chief, Pediatric and Adolescent Dermatology
Medical Director of Research
Children's Hospital and Health Center
San Diego
Dr. Eichenfield has received funding for a clinical study from Sinclair Pharma PLC.

Sarah L. Chamlin, MD
Assistant Professor of Pediatrics and Dermatology
Children's Memorial Hospital, Chicago
Northwestern University, Feinberg School of Medicine
Chicago
Dr. Chamlin is a consultant to Astellas Pharma Inc.

Sheila Fallon Friedlander, MD
Director, Fellowship Training Program
Pediatric and Adolescent Dermatology
Children's Hospital and Health Center, San Diego
Clinical Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Dr. Friedlander is a consultant to Astellas, Connetics Corporation, GlaxoSmithKline, and Novartis AG.

Wm. Philip Werschler, MD, FAAD, FAACS
Assistant Clinical Professor in Medicine/Dermatology
University of Washington
Seattle
Dr. Werschler has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience

To view the supplement, click the image above.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience

To view the supplement, click the image above.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience

To view the supplement, click the image above.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 30th Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• New Options Spur Interest in Combination Treatment

• Preventive Skin Care Forms Basis for Battle Against Sun and Aging

• For Quick Results, Think Nonablative Resurfacing

• Plasma Energy Harnessed for Damaged, Aging Skin

• Horse Chestnut

• New Laser System Offers Another Skin Tx Option

• Maintaining Safety, Integrity of Botulinum Toxin A

Guest Editors

David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
New York, N.Y.
Clinical Grants: Photo Therapeutics, Cynosure, Inc., Neocutis Swiss Technology, Inamed Corporation, Thermage, Inc., and Cutera Inc.; Consultant: BioForm Medical Inc., Lumenis Ltd., and Juva Medical Inc.

Christopher B. Zachary, FRCP
Chair and Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at Irvine
Nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 30th Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• New Options Spur Interest in Combination Treatment

• Preventive Skin Care Forms Basis for Battle Against Sun and Aging

• For Quick Results, Think Nonablative Resurfacing

• Plasma Energy Harnessed for Damaged, Aging Skin

• Horse Chestnut

• New Laser System Offers Another Skin Tx Option

• Maintaining Safety, Integrity of Botulinum Toxin A

Guest Editors

David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
New York, N.Y.
Clinical Grants: Photo Therapeutics, Cynosure, Inc., Neocutis Swiss Technology, Inamed Corporation, Thermage, Inc., and Cutera Inc.; Consultant: BioForm Medical Inc., Lumenis Ltd., and Juva Medical Inc.

Christopher B. Zachary, FRCP
Chair and Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at Irvine
Nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 30th Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• New Options Spur Interest in Combination Treatment

• Preventive Skin Care Forms Basis for Battle Against Sun and Aging

• For Quick Results, Think Nonablative Resurfacing

• Plasma Energy Harnessed for Damaged, Aging Skin

• Horse Chestnut

• New Laser System Offers Another Skin Tx Option

• Maintaining Safety, Integrity of Botulinum Toxin A

Guest Editors

David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
New York, N.Y.
Clinical Grants: Photo Therapeutics, Cynosure, Inc., Neocutis Swiss Technology, Inamed Corporation, Thermage, Inc., and Cutera Inc.; Consultant: BioForm Medical Inc., Lumenis Ltd., and Juva Medical Inc.

Christopher B. Zachary, FRCP
Chair and Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at Irvine
Nothing to disclose.

Copyright © 2006 Elsevier Inc.

This educational supplement to Skin & Allergy News is supported by Neutrogena.
This supplement provides highlights of, and supplemental background information for, the roundtable panel discussion following the Stable Photoprotection Advisory Board Meeting, held October 28, 2005, in Atlanta, GA.

•Topic Highlights
•Faculty
•Target Audience

To view the supplement, click the image above.

Photoprotection and Our Evolving Understanding of the Effects of Ultraviolet Light

• Introduction

• The Effects of UVA/UVB Radiation

• Sunscreens: A Historical Perspective

• Testing Standards and Labeling Issues

• Public Health Concerns

• Developing the Optimal Sunscreen

• UVA-Specific Photoprotectants

Summary

Faculty

Program ChairmanDarrell S. Rigel, MD
Clinical Professor
Deparment of Dermatology
New York University Medical Center
New York, New York
Consultant/Funding for Clinical Grants: Neutrogena Corporation

Diane S. Berson, MD
Assistant Professor
Department of Dermatology
Weill Medical College
Cornell University
New York, New York

Assistant Clinical Professor
Department of Dermatology
New York University School of Medicine
New York, New York
Consultant: Neutrogena Corporation.
She does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Robert J. Ceilly, MD
Clinical Professor
Department of Dermatology
University of Iowa
Des Moines, Iowa
Consultant: OrthoNeutrogena.
He does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Curtis A. Cole, PhD
Senior Director of Technology
Johnson & Johnson Consumer Products Company
Skillman, New Jersey
He is an employee of, directs funding for clinical grants, and holds stock from Johnson & Johnson.

Zoe Diana Draelos, MD
Clinical Associate Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Consultant: Neutrogena Corporation.
She does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Target Audience

This supplement has been developed for dermatologists and other health care professionals who are concerned with issues involving photoprotection and who recommend sunscreen products to their patients.

Copyright © 2006 Elsevier Inc.

This educational supplement to Skin & Allergy News is supported by Neutrogena.
This supplement provides highlights of, and supplemental background information for, the roundtable panel discussion following the Stable Photoprotection Advisory Board Meeting, held October 28, 2005, in Atlanta, GA.

•Topic Highlights
•Faculty
•Target Audience

To view the supplement, click the image above.

Photoprotection and Our Evolving Understanding of the Effects of Ultraviolet Light

• Introduction

• The Effects of UVA/UVB Radiation

• Sunscreens: A Historical Perspective

• Testing Standards and Labeling Issues

• Public Health Concerns

• Developing the Optimal Sunscreen

• UVA-Specific Photoprotectants

Summary

Faculty

Program ChairmanDarrell S. Rigel, MD
Clinical Professor
Deparment of Dermatology
New York University Medical Center
New York, New York
Consultant/Funding for Clinical Grants: Neutrogena Corporation

Diane S. Berson, MD
Assistant Professor
Department of Dermatology
Weill Medical College
Cornell University
New York, New York

Assistant Clinical Professor
Department of Dermatology
New York University School of Medicine
New York, New York
Consultant: Neutrogena Corporation.
She does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Robert J. Ceilly, MD
Clinical Professor
Department of Dermatology
University of Iowa
Des Moines, Iowa
Consultant: OrthoNeutrogena.
He does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Curtis A. Cole, PhD
Senior Director of Technology
Johnson & Johnson Consumer Products Company
Skillman, New Jersey
He is an employee of, directs funding for clinical grants, and holds stock from Johnson & Johnson.

Zoe Diana Draelos, MD
Clinical Associate Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Consultant: Neutrogena Corporation.
She does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Target Audience

This supplement has been developed for dermatologists and other health care professionals who are concerned with issues involving photoprotection and who recommend sunscreen products to their patients.

Copyright © 2006 Elsevier Inc.

This educational supplement to Skin & Allergy News is supported by Neutrogena.
This supplement provides highlights of, and supplemental background information for, the roundtable panel discussion following the Stable Photoprotection Advisory Board Meeting, held October 28, 2005, in Atlanta, GA.

•Topic Highlights
•Faculty
•Target Audience

To view the supplement, click the image above.

Photoprotection and Our Evolving Understanding of the Effects of Ultraviolet Light

• Introduction

• The Effects of UVA/UVB Radiation

• Sunscreens: A Historical Perspective

• Testing Standards and Labeling Issues

• Public Health Concerns

• Developing the Optimal Sunscreen

• UVA-Specific Photoprotectants

Summary

Faculty

Program ChairmanDarrell S. Rigel, MD
Clinical Professor
Deparment of Dermatology
New York University Medical Center
New York, New York
Consultant/Funding for Clinical Grants: Neutrogena Corporation

Diane S. Berson, MD
Assistant Professor
Department of Dermatology
Weill Medical College
Cornell University
New York, New York

Assistant Clinical Professor
Department of Dermatology
New York University School of Medicine
New York, New York
Consultant: Neutrogena Corporation.
She does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Robert J. Ceilly, MD
Clinical Professor
Department of Dermatology
University of Iowa
Des Moines, Iowa
Consultant: OrthoNeutrogena.
He does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Curtis A. Cole, PhD
Senior Director of Technology
Johnson & Johnson Consumer Products Company
Skillman, New Jersey
He is an employee of, directs funding for clinical grants, and holds stock from Johnson & Johnson.

Zoe Diana Draelos, MD
Clinical Associate Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Consultant: Neutrogena Corporation.
She does not have any stock interests, equity interests, or patent-licensing arrangements that could be considered a conflict of interest for this supplement.

Target Audience

This supplement has been developed for dermatologists and other health care professionals who are concerned with issues involving photoprotection and who recommend sunscreen products to their patients.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 30th Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Evolving Clinical Roles of LED, Fillers, Botulinum Toxin

• Combining New and Traditional Techniques Provide Maximal Benefits to Patients

• Laser Technique Zaps Focal Areas of Excess Fat

• Is a Cosmetic Practice for You? Consider These Tips

• Ferulic Acid

• Examine Patient Motivation For Cosmetic Surgery

• Fillers: Beyond the Mythic 'Ideal'

• Injectable Silicone Called a Safe, Elegant Filler

• Pain-Relief Options Available For Cosmetic Procedures

Guest Editors

David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Hackensack, N.J.
Clinical Grants: Photo Therapeutics, Cynosure, Inc., Neocutis Swiss Technology, Inamed Corporation, Thermage, Inc., and Cutera Inc.; Consultant: BioForm Medical Inc., Lumenis Ltd., and Juva Medical Inc. He discusses the off-label use of Mentor Corporation, Inamed, and Juva products.

Christopher B. Zachary, FRCP
Chair and Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at Irvine
Nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 30th Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Evolving Clinical Roles of LED, Fillers, Botulinum Toxin

• Combining New and Traditional Techniques Provide Maximal Benefits to Patients

• Laser Technique Zaps Focal Areas of Excess Fat

• Is a Cosmetic Practice for You? Consider These Tips

• Ferulic Acid

• Examine Patient Motivation For Cosmetic Surgery

• Fillers: Beyond the Mythic 'Ideal'

• Injectable Silicone Called a Safe, Elegant Filler

• Pain-Relief Options Available For Cosmetic Procedures

Guest Editors

David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Hackensack, N.J.
Clinical Grants: Photo Therapeutics, Cynosure, Inc., Neocutis Swiss Technology, Inamed Corporation, Thermage, Inc., and Cutera Inc.; Consultant: BioForm Medical Inc., Lumenis Ltd., and Juva Medical Inc. He discusses the off-label use of Mentor Corporation, Inamed, and Juva products.

Christopher B. Zachary, FRCP
Chair and Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at Irvine
Nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 30th Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Evolving Clinical Roles of LED, Fillers, Botulinum Toxin

• Combining New and Traditional Techniques Provide Maximal Benefits to Patients

• Laser Technique Zaps Focal Areas of Excess Fat

• Is a Cosmetic Practice for You? Consider These Tips

• Ferulic Acid

• Examine Patient Motivation For Cosmetic Surgery

• Fillers: Beyond the Mythic 'Ideal'

• Injectable Silicone Called a Safe, Elegant Filler

• Pain-Relief Options Available For Cosmetic Procedures

Guest Editors

David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Hackensack, N.J.
Clinical Grants: Photo Therapeutics, Cynosure, Inc., Neocutis Swiss Technology, Inamed Corporation, Thermage, Inc., and Cutera Inc.; Consultant: BioForm Medical Inc., Lumenis Ltd., and Juva Medical Inc. He discusses the off-label use of Mentor Corporation, Inamed, and Juva products.

Christopher B. Zachary, FRCP
Chair and Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at Irvine
Nothing to disclose.

Copyright © 2006 Elsevier Inc.